Sharsti Sandall
Vice President & Head, ADC Discovery, Oncology Research Pfizer
Sharsti Sandall, is an Executive Director in Pfizer’s Oncology Research group, where she leads the biology and advancement of the company’s ADC portfolio. A scientific leader with more than a decade of experience in oncology drug development (including at Seagen, now part of Pfizer), she has initiated and guided multiple clinical-stage ADC programs, focusing on optimizing target, linker, and payload selection. Sandall holds a PhD in Biomedical Sciences from UC San Diego and completed a Damon Runyon Postdoctoral Fellowship at the Salk Institute.
Seminars
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
- Understanding how to migrate from non-selective ADC payloads
- Debating the right properties for a next-generation payload and linker: Can (or should?) any small molecule therapeutic be developed into an ADC?
- Debating the right strategy for dual payload ADCs
- Understanding ADC toxicity and developability for next generation conjugates
Rejoin the Discovery Chemistry speakers for a closing panel discussion to break down the key learnings and future directions in ADC chemistry and MoA innovation. Listen and engage with your fellow attendees as they discuss showing promise within novel cytotoxic, non-cytotoxic and dual payload ADCs, and what still needs to be proven to unlock differentiation to combat patient resistance.
